ACT Brief: Global Trials Scale Up, Site-Centric Startup Gains Focus, and Pfizer Expands Vaccine Partnerships

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• A new Applied Clinical Trials contributed article examines how global clinical development has become more technology-enabled, regulated, and geographically diversified. Emerging markets—particularly in Asia-Pacific and China—are driving a growing share of trial starts, while decentralized and hybrid trial models are expanding access and participation. The article highlights how CRO partnerships, digital platforms, and evolving regulatory guidance are reshaping global trial execution around scale, speed, and patient-centricity.
• In the final installment of his Applied Clinical Trials video interview, Brian Mallon of ICON says accelerating study startup requires sponsors and CROs to better center the human experience of site staff. He emphasizes the importance of genuine site partnerships, clearer timelines, and meeting sites within their existing systems and workflows. Mallon notes that valuing site expertise and engagement is essential to maintaining momentum and improving activation performance.
• Novavax has entered a non-exclusive licensing agreement with Pfizer worth up to $530 million, granting Pfizer access to Novavax’s Matrix-M adjuvant technology for vaccine development. The deal includes $30 million upfront and potential milestone payments and royalties, with Pfizer responsible for development and commercialization. Executives say the agreement reflects Novavax’s shift toward partnership-driven growth and strengthens Pfizer’s access to diversified vaccine platforms.

That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.